News

1 Ultra-High-Yield Dividend Stock Down 57% to Buy Hand Over Fist
Second, Pfizer's forward dividend yield stands at 7.47%. At first glance, the drugmaker's dividend payout ratio of 122.5% ...
U.S. Pharmaceutical Imports Might Soon Face Tariffs: 3 Stocks That Could Tumble as a Result
The tariff war the U.S. is waging against most of the world stabilized somewhat earlier this month. But let's face facts -- ...
STAT17h
FDA gives Covid vaccine manufacturers instructions for next fall’s shot
The notice came shortly after an advisory panel meeting at which members debated the pros and cons of asking manufacturers to ...
COVID shots should target newer strains of JN.1 variant, US FDA advisers say
U.S. Food and Drug Administration advisers unanimously recommended on Thursday that COVID-19 vaccines for the 2025-26 period ...
Here's what to know about the FDA's COVID-19 vaccine changes
The FDA will limit the vaccine’s availability later this year to older adults and those who may be at risk of severe illness.
Fierce Pharma20h
Fierce Pharma Asia—Pfizer's PD-1xVEGF bet; An Alzheimer's blood test approval; Samsung's biosim spinoff
Pfizer is paying $1.25 billion to join the PD-(L1)xVEGF bispecific race. | Pfizer is paying $1.25 billion to join the ...
Uncertainty loomed as FDA advisors met to discuss this year’s COVID shot
At the outset of the meeting, the FDA's new top vaccine regulator, Vinay Prasad, said he and FDA leaders wanted to "give people a little more time to digest the policy." He said that the FDA is still ...
STAT1dOpinion
To address the pharmacy crisis, doctors should dispense some drugs
Point-of-care medication dispensing offers a return to a more straightforward approach, common to physician practices ...
Health News Florida1d
Vaccine advisers to the FDA recommended changes to COVID vaccines
Advisers to the Food and Drug Administration met Thursday to help decide which variant of the virus that causes COVID should ...
With vaccine approval process set to change, FDA advisers leave wiggle room in annual Covid-19 shot recommendations
A group of experts who advise the US Food and Drug Administration on its vaccine decisions voted unanimously Thursday to make ...
Astellas and Pfizer's XTANDI™ (enzalutamide) Shows Long-Term Overall Survival in Metastatic Hormone-Sensitive Prostate Cancer
Five-year follow-up data from the Phase 3 ARCHES trial shows XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces risk of death by 30% After a median follow-up of 61.4 months, ...